# Merck

Type: Company (MRK)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/merck
Canonical HTML page: https://gethealthbrief.com/entity/merck

## Timeline

- **2028**: Keytruda Patent Expiration — The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
- **2027**: NXT 41X Launch — Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
- **2027**: Pipeline Integration — Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
- **2026-Q4**: Expected Closing — Anticipated completion of the acquisition following regulatory and shareholder approvals.
- **2026-Q2**: Bumble 2.0 Launch — Targeted launch of AI-enabled platform experience.
- **2026-03-25**: Acquisition Announced — Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
- **2026-03-11**: Codexis CDMO Expansion — Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
- **2026**: Elutia FDA Milestone — Expected FDA submission for NXT 41X product line.
- **2025-12-31**: Elutia Divestiture — Completed $88M sale of bioenvelope business to Boston Scientific.

## Recent coverage (4 stories)

### Moderna 177% Surge Lifts S&P 500 Healthcare Sector 2.9% to Record
2026-08-20 00:37:19 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 4

Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Full story: https://gethealthbrief.com/story/moderna-177-pct-healthcare-sector-record

### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions
2026-07-16 22:00:46 · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access

### Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
2026-03-25 16:34:35 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Full story: https://gethealthbrief.com/story/merck-terns-acquisition-oncology-strategy

### MedTech and Life Sciences Pivot Toward AI Efficiency and Asset Optimization
2026-03-12 00:13:28 · Sentiment: Positive · Impact: 6/10 · Sources: 9

The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Full story: https://gethealthbrief.com/story/medtech-life-sciences-ai-efficiency-asset-optimization

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.